

Douglas W. Axelrod. M.D., Ph.D.
Chief Medical Officer & Senior Vice President, Development

Prior to Ambrx, Dr. Axelrod served as Vice President of R&D for Discovery, Early Development and Product Development at Procter & Gamble Pharmaceuticals. In this role, he accelerated the discovery process, improved the discovery to early development transition and led efficiencies in product development. Earlier in his career at P&G Pharmaceuticals, he led the Worldwide Clinical Bone group, stewarding drugs such as Didronel™ and Actonel™ through late clinical development and regulatory approvals, where they became among the leading osteoporosis therapies worldwide. Dr Axelrod was also a major architect of the Genome Research Institute at the University of Cincinnati School of Medicine and served as its Professor of Genome Sciences. Dr. Axelrod obtained his Ph.D. in the Department of Cell Biology at Baylor College of Medicine. He obtained his MD at the same institution, where he completed his Residency in Internal Medicine, Fellowship in Endocrinology and Metabolism and served as Visiting Scientist in the Department of Cell Biology at MD Anderson Tumor Institute before joining P&G Pharmaceuticals in 1990.